Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer
NCT01073865
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
222
Enrollment
INDUSTRY
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
ZD9393 (Zoladex) 10.8 mg
DRUG:
ZD9393 (Zoladex) 3.6 mg
Sponsor
AstraZeneca